Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial

Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial

This study is testing whether pathogen reduced platelets can control bleeding as well as non-pathogen reduced platelets (otherwise known as large volume delayed sampling).

This is a pilot clinical trial to assess the post-operative bleeding in children who receive pathogen-reduced (PR) platelet transfusions versus standard (large volume delayed sampling - LVDS) platelet transfusions both during and for 24 hours following cardiopulmonary bypass surgery.

Inclusion Criteria:

• Male or female 0 up to and including 18 years of age
• Undergoing elective cardiopulmonary bypass surgery
• Are planned to have a chest tube placed in the operating room prior to chest closure

Exclusion Criteria:

• >/=19 years of age
• Preterm infants (less than 38-week gestational age at time of surgery)
• On extracorporeal membrane oxygenation (ECMO) or ventricular assist device prior to surgery
• Family requests limitation of blood products (i.e. Jehovah's Witness)
• Congenital bleeding disorder
• Are planned to require ECMO post-op
• Previously enrolled in the study